We can already tinker with human DNA to treat diseases. But being able to edit RNA allows for even more precision – and fewer ...

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...

Nature is adept at designing proteins. Scientists are even better. But artificial intelligence holds the promise of improving ...

This clearance is seen as reducing the risk associated with the therapy and is a distinguishing feature compared to competitors ... Kostas Biliouris also recognizes the broader implications of RNA ...

The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application ...

Korro Bio has secured approvals in Australia to commence the Phase I/IIa trial of KRRO-110, aimed at treating AATD.

Find out how Google DeepMind's AlphaFold3 platform could help scientists revolutionize the field of drug discovery.

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire ...

Novartis has acquired Kate Therapeutics for up to $1.1 billion, the companies said today, in a deal that expands the buyer’s ...

Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...

In exchange, Novartis is gaining Kate Therapeutics' preclinical adeno-associated virus-based gene therapy candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic ...